JDRF and Lilly Canada requesting applications from postdoctoral fellows engaged in clinical type 1 diabetes research

Toronto, ON, Fri May 26, 2017 – JDRF Canadian Clinical Trial Network (JDRF CCTN) is pleased to announce that Eli Lilly Canada Inc. (Lilly Canada) has provided $120,000 in support of two CCTN postdoctoral fellows for one year in the sum of $60,000 each.

These awards are intended to provide each recipient with partial salary support for one year, enabling them to progress as an independent investigator. Through these fellowships, researchers will take advantage of the nationwide investment in clinical translation in type 1 diabetes (T1D) research. Applicants must hold an MD, PhD, MD/PhD, or equivalent, and be within seven years of receiving their doctoral degree. There are no citizenship requirements, but applicants must hold an appointment and be engaged in research at a Canadian institution. Those currently involved in human clinical research and/or research with potential to lead to clinical translation of new advances in T1D will be given highest priority.

“JDRF remains the leading nonprofit organization funding research into the cure, prevention, and treatment of T1D, and is committed to turning type one into type none,” says JDRF Canada president and CEO Dave Prowten. “By joining with Lilly Canada to support our best and brightest young Canadian scientists focused on T1D clinical research, we are working to change the face of this life-altering condition.”

Applicants demonstrating collaborations that build upon existing JDRF CCTN projects and infrastructure are especially encouraged to apply. Applicants from institutions not currently affiliated with CCTN, however, are eligible to apply.

These training awards are expected to augment JDRF CCTN’s investment in T1D research nationwide. They will be administered and managed by JDRF CCTN.

Applicants are encouraged to review descriptions of JDRF’s current Research Priority Areas.

Read more about the application process.

About Lilly Canada

Eli Lilly Canada was established in 1938, the result of a research collaboration with scientists at the University of Toronto which eventually produced the world’s first commercially-available insulin. Lilly Canada now employs 400 people across the country, working in the areas of oncology, diabetes, autoimmunity, neurodegeneration, and pain. To learn more about Lilly Canada, please visit us at www.lilly.ca.

About JDRF

JDRF is the leading global organization funding type 1 diabetes (T1D) research. JDRF’s goal is to progressively remove the impact of T1D from people’s lives until we achieve a world without T1D. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D. JDRF is the largest charitable supporter of T1D research. For more information, please visit jdrf.ca.

Media contact

Sherene Chen-See
Marketing Communications Content Strategist, JDRF Canada
schensee@jdrf.ca
647.789.2368

 

 
Lets turn type one into type none